報價延遲最少15分鐘:2025/08/25 12:32 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.075 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.08/-0.79
|
|
企業價值
1.22B
|
| 資產負債 |
|
每股賬面淨值
1.97
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
940.20M
|
|
每股收益
11.42
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/25 12:32 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days. |
